The document discusses several intellectual property issues that can arise from university licensing agreements and clinical trial agreements. It provides hypothetical scenarios and proposes solutions to resolve potential problems regarding exclusivity of licenses, patent infringement suits, ownership of inventions from clinical trials, and premature publication of clinical trial results. The key is for universities and companies to negotiate agreements that balance their interests and allow shared development of new drugs and technologies for patient benefit.

1. Nina Ashton Vice President, Intellectual Property Elan Pharmaceuticals, Inc. [email_address] Resolving IP Issues Related to University Agreements AUTM February 13, 2009